glp-1 during pregnancy GLP-1-Mediated and Neonatal Complications in Mice Frontiers | Effects of GLP-1

As their use has expanded, questions about potential cancer risks have emerged, prompting both patients and healthcare providers to seek clarity on the safety profile of these medications

Early Treatment Diabetic Retinopathy Study Research Group

*Correspondence: Yaqiu Jiang, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era

Because the prevalence of CVD in the population with T2DM is around 32% [33], at least one fourth of the average patient with T2DM is possible a candidate for the use of the GLP-1RA, or sodium-glucose transporter-2 inhibitors [34], to improve the MACE outcome